@progret2024.bsky.socialInside ProgRET: discover our PhD projects.🔬
🎥 This month: Hossein D. Banadaki (DC7). He uses ASOs to silence harmful genetic messages while preserving healthy ones. 🧬
📍 Radboudumc, Nijmegen, The Netherlands
#msca #inheritedretinaldisease #sciencecommunication #phd #rnatherapeutics
@tenuretracker.bsky.socialUniversity of British Columbia is hiring:
Research Associate in Next-Generation RNA Therapeutics
@vicotx.bsky.socialVico's Piotr Putaj will present a poster on our REACH chemistry platform at #OTS2026, October 11–14 in Denver.
Learn how REACH is designed to enhance productive uptake of ASOs in the central nervous system. Attending? Stop by Piotr's poster!
#RNATherapeutics
@tyokota.bsky.socialNew Yokota Lab editorial: RNA therapies for rare neuromuscular diseases, from clinical progress to personalized N-of-1 treatment.
Peer-reviewed accepted manuscript: doi.org/10.1080/1471...
@rti-umasschan.bsky.socialHot off the press from the RTI: Fanconi anemia pathway disruption drives lomustine sensitivity in glioma
buff.ly/oJp5GyS #RNA #RNATherapeutics
@rti-umasschan.bsky.socialHot off the press from the RTI: #RNATherapeutics
@rti-umasschan.bsky.socialHot off the press from the RTI: Ex vivo machine perfusion enables robust and widespread lipophilic-conjugated siRNA delivery to the porcine lung
buff.ly/XcevKPc #RNA #RNATherapeutics
@newsramp.comTransCode Therapeutics (NASDAQ: RNAZ) expands its global patent portfolio with new IP grants in Australia and Japan covering RNA-based nanoparticle therapies targeting multiple cancers, including breast, lung, and pancreatic. #Oncology #RNATherapeutics
@newsramp.comTransCode Therapeutics (NASDAQ: RNAZ) expands its global patent portfolio with new IP grants in Australia and Japan covering RNA-based nanoparticle therapies targeting multiple cancers, including breast, lung, and pancreatic. #Oncology #RNATherapeutics
@rti-umasschan.bsky.socialHot off the press from the RTI: Nucleic acid therapeutics in neurodegenerative disorders: emerging technologies and clinical landscape
buff.ly/qJUGYVq #RNA #RNATherapeutics
@rti-umasschan.bsky.socialHot off the press from the RTI: Population genetics, trait mapping and fungal pathogen surveillance using untargeted sequencing in timber rattlesnakes (Crotalus horridus)
buff.ly/mbA1ICW #RNA #RNATherapeutics
@swissinitiativerna.bsky.socialWelcome Microsynth – The Swiss DNA Company – as our first Booth Sponsor for RNATX 2027!
Join us on 28 January 2027 in Bern.
Register: www.conftool.net/chrnat2027
More info: rnatx.ch
@rti-umasschan.bsky.socialHot off the press from the Watts & Khvorova labs: Albumin-binding dendrimer-conjugated siRNA enables safe and effective gene silencing throughout the central nervous system buff.ly/FUvJ0hf
#RNA #RNATherapeutics
@otdc-2026.bsky.social⏰ The deadline is TODAY!
Register for OTDC 2027 and connect with advances in Oligonucleotide Therapeutics, RNA Technologies, Drug Delivery, CRISPR & Aptamer Technologies.
📅 May 11–12, 2027 | Boston + Hybrid
🔗 oligo-nucleotide.com
@otdc-2026.bsky.socialFrom molecular insights to life-changing therapies 🧬
OTDC 2027 brings together emerging advances in Oligonucleotide Therapeutics, RNA Technologies, Drug Delivery, CRISPR & Aptamer Technologies.
📅 May 11–12, 2027
📍 Boston | Hybrid
🔗 oligo-nucleotide.com
@remixtx.bsky.socialAt #DrugDiscoveryOnTarget, our CSO, Dominic Reynolds, will highlight REM-422, our first-in-class mRNA degrader targeting the MYB oncogene, and discuss how our REMaster® platform is enabling new approaches to previously undruggable RNA targets.
@moltherapy.bsky.socialTODAY at 11 AM CDT: Molecular Therapy Presents - AI-Powered Precision Medicine: From Biomarker Discovery to Therapeutic Design and Delivery
Join us for this exciting FREE webinar today: http://dlvr.it/TVcMM4
#ArtificialIntelligence #GeneTherapy #RNAtherapeutics #ASGCT
@otdc-2026.bsky.social🧬 From Nucleic Acids to Real-World Impact.
OTDC 2027 explores advances in oligonucleotide therapeutics, RNA medicines, and innovative delivery technologies.
📅 May 11–12, 2027 | 📍 Boston, MA & Virtual
🔗 oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics #DrugDelivery
@otdc-2026.bsky.social🧬 Small molecules. Big possibilities.
OTDC 2027 explores emerging advances in oligonucleotide therapeutics, RNA medicines, and innovative delivery technologies.
📅 May 11–12, 2027 | 📍 Boston, MA | 🌐 Hybrid
🔗 oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics #DrugDelivery #RNAMedicine
@otdc-2026.bsky.social🧬 Molecular frontiers. Therapeutic possibilities.
OTDC 2027 explores new directions in oligonucleotide therapeutics, RNA medicines, and delivery science.
📅 May 11–12, 2027 | Boston, MA & Virtual
🔗 oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics
